We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Xywav

News List

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults drugs
August 16, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults.
Xywav Gets FDA Approval to Treat Rare Sleep Disorder drugs
August 16, 2021
The drug Xywav has been approved for expanded use in adults with the rare sleep disorder idiopathic hypersomnia, the U.S. Food and Drug Administration said Thursday.
FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment fda.gov
August 13, 2021
The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep.